The article offers information about immunotherapies for B-Cell Acute Lymphocytic Leukemia. Topics discussed include improvements in therapies targeting immune responses against solid tumors; improvement in survival and relapse rates in treatments with rituximab; and approval of use of Blinatumomab, a bispecific monoclonal antibody combining anti-CD19 with anti-CD3.